GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Rachel Norris, MD ...

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...

Beyond called off its $40 million investment deal with The Container Store. The parent company of Bed, Bath and Beyond in November cast doubt on the deal, expressing concerns the specialty retailer ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

The vagus nerve is a key part of the parasympathetic nervous system influencing bodily functions like heart rate digestion ...

The one-two punch sent newly consolidated shares tumbling despite progress on its non-hallucinogenic depression treatment.

The potential legalization of magic mushrooms is heading to Olympia next week as state lawmakers prepare to hear testimony on two bills ...